DG

Daniel Gil, PhD

Chief Executive Officer

Pelage Pharmaceuticals

Pelage Pharmaceuticals Pipeline

DrugIndicationPhase
PP405Androgenetic Alopecia (Pattern Hair Loss)Phase 2a